GMAB stock slides as Genmab scraps late-stage acasunlimab cancer therapy
NEW YORK, December 30, 2025, 1:54 PM ET — Regular session Genmab A/S’s U.S.-listed shares (GMAB) fell 3.3% to $31.45 in Tuesday’s regular session. The stock traded between $31.40 and $32.06 after opening at $31.98, with about 1.9 million shares
